GSK Acquires Exclusive Rights for Antibody Drug Conjugate
GSK plc and Syndivia, a private biotechnology company, have announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical ADC for metastatic castration-resistant prostate cancer (mCRPC).
Approximately 1.4 million men worldwide are diagnosed with prostate cancer each year, with 10-20% developing advanced disease within five years.
For patients with mCRPC, targeted treatment options are limited, and standard care options can be difficult to access and poorly tolerated, resulting in modest efficacy outcomes and low survival rates.
Survival rates for these patients are low, with a 5-year survival rate of approximately 30% and a median survival of approximately two years.
GSK's acquisition aims to address this unmet medical need and provide new treatment options for patients with mCRPC.
Author's summary: GSK gains exclusive rights to develop a new ADC for prostate cancer.
More News
- Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE
- Investors call for more plant-based proteins from food manufacturers and retailers: FAIRR
- MLB: The Last 10 World Series MVPs
- The Tech Circus: AI, Venture Capital, and Elon Musk's Wikipedia Remix
- GSK secures rights to Syndivia’s ADC asset for prostate cancer
- Spicy Tomato And Sausage Rigatoni
- Nanoscale Pixels to Advance Compact Augmented Reality Eyewear
- Report: Food Companies Are Not Effectively Meeting Demand for Plant-Based Proteins - vegconomist - the vegan business magazine
- Main Capital invests in logistics platform Shippingbo | PE Hub
- Trump’s Leadership Challenges Democrats’ Distorted Narrative Effectively